DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,764 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,159,659 | +9.1% | 4,641 | +9.1% | 0.58% | -10.0% |
Q1 2024 | $1,062,559 | +5.1% | 4,255 | -1.2% | 0.65% | -8.1% |
Q4 2023 | $1,011,006 | -4.6% | 4,306 | +0.8% | 0.70% | +13.0% |
Q3 2023 | $1,059,635 | +4.2% | 4,271 | +0.8% | 0.62% | +5.2% |
Q2 2023 | $1,017,360 | -11.5% | 4,239 | -7.1% | 0.59% | -16.9% |
Q1 2023 | $1,150,059 | -4.7% | 4,563 | +0.4% | 0.71% | -1.8% |
Q4 2022 | $1,206,334 | +6.5% | 4,545 | +3.6% | 0.72% | -36.1% |
Q3 2022 | $1,133,000 | +1.8% | 4,387 | -0.1% | 1.13% | +3.4% |
Q2 2022 | $1,113,000 | -8.6% | 4,391 | +4.3% | 1.10% | -12.9% |
Q1 2022 | $1,218,000 | -7.5% | 4,210 | +5.2% | 1.26% | +26.7% |
Q4 2021 | $1,317,000 | -3.9% | 4,002 | -11.0% | 0.99% | -2.8% |
Q3 2021 | $1,370,000 | +9.8% | 4,499 | +0.4% | 1.02% | +13.7% |
Q2 2021 | $1,248,000 | +30.4% | 4,479 | +5.4% | 0.90% | +21.0% |
Q1 2021 | $957,000 | +14.7% | 4,250 | +13.2% | 0.74% | +17.5% |
Q4 2020 | $834,000 | – | 3,754 | – | 0.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |